TOFACITINIB CITRATE | A218821 | CONCORD BIOTECH LTD
2 strengths0 unique patents0 unique exclusivities
Reference Listed Drug: XELJANZ(TE code: AB) Products (2)
Sort:
No patent or exclusivity listings for this strength.
ADDED7/1/2026
Concord Biotech Ltd received FDA approval for TOFACITINIB CITRATE under application 218821, supplement 002.
ADDED7/1/2026
Concord Biotech Ltd received FDA approval for tofacitinib citrate (ANDA 218821), a generic formulation of the JAK inhibitor.